These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 11406743)

  • 1. Drug interactions as a cause of overanticoagulation on phenprocoumon or acenocoumarol predominantly concern antibacterial drugs.
    Penning-van Beest FJ; van Meegen E; Rosendaal FR; Stricker BH
    Clin Pharmacol Ther; 2001 Jun; 69(6):451-7. PubMed ID: 11406743
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overanticoagulation associated with combined use of antibacterial drugs and acenocoumarol or phenprocoumon anticoagulants.
    Visser LE; Penning-van Bees FJ; Kasbergen AA; De Smet PA; Vulto AG; Hofman A; Stricker BH
    Thromb Haemost; 2002 Nov; 88(5):705-10. PubMed ID: 12428081
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overanticoagulation associated with combined use of lactulose and acenocoumarol or phenprocoumon.
    Visser LE; Penning-van Beest FJ; Wilson JH; Vulto AG; Kasbergen AA; De Smet PA; Hofman A; Stricker BH
    Br J Clin Pharmacol; 2004 Apr; 57(4):522-4. PubMed ID: 15025752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allelic variants of cytochrome P450 2C9 modify the interaction between nonsteroidal anti-inflammatory drugs and coumarin anticoagulants.
    Visser LE; van Schaik RH; van Vliet M; Trienekens PH; De Smet PA; Vulto AG; Hofman A; van Duijn CM; Stricker BH
    Clin Pharmacol Ther; 2005 Jun; 77(6):479-85. PubMed ID: 15961979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overanticoagulation associated with combined use of antifungal agents and coumarin anticoagulants.
    Visser LE; Penning-van Beest FJ; Kasbergen AA; De Smet PA; Vulto AG; Hofman A; Stricker BH
    Clin Pharmacol Ther; 2002 Jun; 71(6):496-502. PubMed ID: 12087353
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characteristics of anticoagulant therapy and comorbidity related to overanticoagulation.
    Penning-van Beest FJ; van Meegen E; Rosendaal FR; Stricker BH
    Thromb Haemost; 2001 Aug; 86(2):569-74. PubMed ID: 11522005
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Possible drug-drug interaction between high-dose esomeprazole and phenprocoumon.
    Becker ML; Franken WP; Karapinar F; Verzijl-Zeegers R; Schalekamp T; van der Hoeven RT
    Eur J Clin Pharmacol; 2015 Dec; 71(12):1461-5. PubMed ID: 26400679
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The risk of bleeding complications in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon.
    Visser LE; van Schaik RH; van Vliet M; Trienekens PH; De Smet PA; Vulto AG; Hofman A; van Duijn CM; Stricker BH
    Thromb Haemost; 2004 Jul; 92(1):61-6. PubMed ID: 15213846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Main comedications associated with major bleeding during anticoagulant therapy with coumarins.
    Penning-van Beest F; Erkens J; Petersen KU; Koelz HR; Herings R
    Eur J Clin Pharmacol; 2005 Jul; 61(5-6):439-44. PubMed ID: 15947920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of major bleeding during concomitant use of antibiotic drugs and coumarin anticoagulants.
    Penning-van Beest FJ; Koerselman J; Herings RM
    J Thromb Haemost; 2008 Feb; 6(2):284-90. PubMed ID: 18031295
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug-drug interactions with metronidazole and itraconazole in patients using acenocoumarol.
    Becker ML; van Uden RCAE; Giezen TJ; Meijer K; Houtenbos I; van den Bemt PMLA
    Eur J Clin Pharmacol; 2020 Oct; 76(10):1457-1464. PubMed ID: 32524154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacogenetic differences between warfarin, acenocoumarol and phenprocoumon.
    Beinema M; Brouwers JR; Schalekamp T; Wilffert B
    Thromb Haemost; 2008 Dec; 100(6):1052-7. PubMed ID: 19132230
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The risk of overanticoagulation in patients with heart failure on coumarin anticoagulants.
    Visser LE; Bleumink GS; Trienekens PH; Vulto AG; Hofman A; Stricker BH
    Br J Haematol; 2004 Oct; 127(1):85-9. PubMed ID: 15384981
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Subtherapeutic oral anticoagulant therapy: frequency and risk factors.
    Rombouts EK; Rosendaal FR; van der Meer FJ
    Thromb Haemost; 2009 Mar; 101(3):552-6. PubMed ID: 19277419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of bleeding and antibiotic use in patients receiving continuous phenprocoumon therapy. A case-control study nested in a large insurance- and population-based German cohort.
    Abbas S; Ihle P; Harder S; Schubert I
    Thromb Haemost; 2014 May; 111(5):912-22. PubMed ID: 24429904
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lifestyle and diet as risk factors for overanticoagulation.
    Penning-van Beest FJ; Geleijnse JM; van Meegen E; Vermeer C; Rosendaal FR; Stricker BH
    J Clin Epidemiol; 2002 Apr; 55(4):411-7. PubMed ID: 11927211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic quality control of oral anticoagulant therapy comparing the short-acting acenocoumarol and the long-acting phenprocoumon.
    Gadisseur AP; van der Meer FJ; Adriaansen HJ; Fihn SD; Rosendaal FR
    Br J Haematol; 2002 Jun; 117(4):940-6. PubMed ID: 12060134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Coumarin anticoagulants and co-trimoxazole: avoid the combination rather than manage the interaction.
    Schalekamp T; van Geest-Daalderop JH; Kramer MH; van Holten-Verzantvoort AT; de Boer A
    Eur J Clin Pharmacol; 2007 Apr; 63(4):335-43. PubMed ID: 17318526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characteristics and quality of oral anticoagulation treatment in pediatric patients in the Netherlands based on the CAPS cohort.
    Maagdenberg H; Bierings MB; van Ommen CH; van der Meer FJM; Appel IM; Tamminga RYJ; de Boer A; Maitland-van der Zee AH
    J Thromb Haemost; 2018 Jan; 16(1):116-124. PubMed ID: 29108090
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proton pump inhibitors and the risk of overanticoagulation during acenocoumarol maintenance treatment.
    Teichert M; van Noord C; Uitterlinden AG; Hofman A; Buhre PN; De Smet PA; Straus S; Stricker BH; Visser LE
    Br J Haematol; 2011 May; 153(3):379-85. PubMed ID: 21418179
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.